Abstract
Purpose
Bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor, is widely used in association with standard chemotherapy in metastatic cancer. Well tolerated, bevacizumab is sometimes associated with serious adverse drug reactions (ADRs). The objective of this study is to describe the profile of ADRs related to bevacizumab and reported to the French Pharmacovigilance system.
Method
All serious cases of ADRs associated with bevacizumab recorded in the French Pharmacovigilance database up to November 31, 2010 were identified and analyzed, focusing on patient information, drug exposure, and characteristics of the ADRs. Categorical variables were compared using the chi-square test when appropriate.
Results
A total of 351 serious cases involving 626 ADRs were recorded in the database during the study interval. The most frequent ADRs reported involved the gastrointestinal system (21.9%). The most frequent ADRs included gastrointestinal perforation (4.8%), thromboembolic events (4.0%), pulmonary embolism (3.2%), hypertension (2.7%), gastrointestinal hemorrhage (2.7%), and cerebral hemorrhage or vascular accident (2.6%). The median duration of bevacizumab exposure was four cycles (range 1–30) when ADRs occurred. In 18 cases of death directly caused by ADRs, 50% occurred after only one cycle. In cases of disability, 40% of ADRs were neurologic: neuropathy, paralysis, and paresis.
Conclusion
To the best of our knowledge, this is the first analysis of bevacizumab safety profile using data collected in a national pharmacovigilance database. Our study confirms the frequency and seriousness of gastrointestinal, thromboembolic, and hemorrhage events with bevacizumab use and provides a picture of the bevacizumab safety profile in daily medical practice, despite intrinsic limitations.
Similar content being viewed by others
Reference
Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28(11):1779–1802
European Medicines Agency. Avastin EPAR—Product information. Available at: www.ema.europa.eu
Arrêté du 28 avril 2005 relatif aux Bonnes Pratiques de Pharmacovigilance. French Official Journal (2005) 9087–9102
Edwards I, Aronson J (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1260
Begaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 40:111–118
Begaud B, Martin K, Haramburu F, Moore N (2002) Rates of spontaneous reporting of adverse drug reactions in France. JAMA 288:1588
Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96(12):1788–1795
Miles D (2008) Management of toxicity in patients receiving therapy with bevacizumab. Eur J Cancer Suppl 6(6):29–39
Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559–568
Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300(19):2277–2285
Elice F, Rodegjiero F (2010) Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thromb Res Suppl 125(2):S55–S57
European Medicines Agency (2010). European Medicines Agency completes its review of Avastin used in breast cancer. News and press release archive, December 16, 2010. Available at: www.ema.europa.eu.
Food and Drug Administration (2010). FDA begins process to remove breast cancer indication from Avastin label. FDA News release, December 16, 2010. Available at: www.fda.gouv
Conflict of interest
None.
Financial support
None.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Taugourdeau-Raymond, S., Rouby, F., Default, A. et al. Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. Eur J Clin Pharmacol 68, 1103–1107 (2012). https://doi.org/10.1007/s00228-012-1232-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-012-1232-7